Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

(2016) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

HPF1/C4orf27 Is a PARP-1-Interacting Protein that Regulates PARP-1 ADP-Ribosylation Activity

(2016) Ian Gibbs-Seymour et al.   MOLECULAR CELL

Poly(ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors Reduce Reactive Gliosis and Improve Angiostatin Levels in Retina of Diabetic Rats

(2016) Mykhailo M. Guzyk et al.   NEUROCHEMICAL RESEARCH

PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair

(2016) E-B Choi et al.   ONCOGENE

Knockdown of PARP-1 Inhibits Proliferation and ERK Signals, Increasing Drug Sensitivity in Osteosarcoma U2OS Cells

(2016) Sheng Li et al.   ONCOLOGY RESEARCH

Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations

(2016) Michal Yalon et al.   PLoS One

A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model

(2016) Corey Saba et al.   PLoS One

RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy

(2016) Adrian P. Wiegmans et al.   Oncotarget

Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1 -Mutant Ovarian Cancer

(2016) Young Eun Choi et al.   Cell Reports

JNK Phosphorylates SIRT6 to Stimulate DNA Double-Strand Break Repair in Response to Oxidative Stress by Recruiting PARP1 to DNA Breaks

(2016) Michael Van Meter et al.   Cell Reports

Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer

(2016) Robert J. Cardnell et al.   PLoS One

PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers

(2015) Jennifer Stanley et al.   BREAST CANCER RESEARCH AND TREATMENT

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours

(2015) Ruth Plummer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Expression of nuclear matrix proteins binding matrix attachment regions in prostate cancer. PARP-1: New player in tumor progression

(2015) Paola Barboro et al.   INTERNATIONAL JOURNAL OF CANCER

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells

(2015) BANU ARUN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination

(2015) Philip Jones et al.   JOURNAL OF MEDICINAL CHEMISTRY

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer

(2015) Linda Henneman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line

(2015) Federica Baldan et al.   International Journal of Endocrinology

Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy

(2015) Hongying Sui et al.   Drug Design Development and Therapy

NF-kB signaling mediates acquired resistance after PARP inhibition

(2015) Yuko Nakagawa et al.   Oncotarget

PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression

(2015) Germano Mariano et al.   Oncotarget

Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications

(2015) See-Hyoung Park et al.   Oncotarget

Successes and Challenges of PARP Inhibitors in Cancer Therapy

(2015) Tiffany K. Ricks et al.   Frontiers in Oncology

Abstract 2965: Olaparib and veliparib as effective PARP inhibitors for cancer prevention in a BRCA1-deficient mouse model

(2015) Ciric To et al.   CANCER RESEARCH

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma

(2015) Sonja J. Gill et al.   PLoS One

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules

(2014) J Murray et al.   BRITISH JOURNAL OF CANCER

PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis

(2014) H. Pu et al.   CARCINOGENESIS

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

(2014) M. A. Smith et al.   CLINICAL CANCER RESEARCH

Double strand break (DSB) repair in heterochromatin and heterochromatin proteins in DSB repair

(2014) Charlène Lemaître et al.   DNA REPAIR

Poly(ADP-ribose) Polymerase 1 (PARP1) Associates with E3 Ubiquitin-Protein Ligase UHRF1 and Modulates UHRF1 Biological Functions

(2014) Mike De Vos et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Poly(ADP-ribose) Polymerase-1 Inhibition in Brain Endothelium Protects the Blood—Brain Barrier under Physiologic and Neuroinflammatory Conditions

(2014) Slava Rom et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Effect of Small-Molecule Modification on Single-Cell Pharmacokinetics of PARP Inhibitors

(2014) G. M. Thurber et al.   MOLECULAR CANCER THERAPEUTICS

PARP-1 Expression is Increased in Colon Adenoma and Carcinoma and Correlates with OGG1

(2014) Tomasz Dziaman et al.   PLoS One

PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma

(2014) Georg Karpel-Massler et al.   PLoS One

Basal Activity of a PARP1-NuA4 Complex Varies Dramatically across Cancer Cell Lines

(2014) Kristin A. Krukenberg et al.   Cell Reports

CTCF Haploinsufficiency Destabilizes DNA Methylation and Predisposes to Cancer

(2014) Christopher J. Kemp et al.   Cell Reports

Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells

(2013) M Venere et al.   CELL DEATH AND DIFFERENTIATION

Estrogen Receptor Beta-Mediated Proliferative Inhibition and Apoptosis in Human Breast Cancer by Calycosin and Formononetin

(2013) Jian Chen et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?

(2013) Peter Bouwman et al.   CLINICAL CANCER RESEARCH

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

(2013) Y. Shen et al.   CLINICAL CANCER RESEARCH

Poly(ADP-ribose) Polymerase 1 Is a Key Regulator of Estrogen Receptor α-dependent Gene Transcription

(2013) Fengxiao Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

(2013) Shahneen K Sandhu et al.   LANCET ONCOLOGY

TDP1 and PARP1 Deficiency Are Cytotoxic to Rhabdomyosarcoma Cells

(2013) Hok Khim Fam et al.   MOLECULAR CANCER RESEARCH

Mechanisms of resistance to therapies targeting BRCA-mutant cancers

(2013) Christopher J Lord et al.   NATURE MEDICINE

Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair

(2013) M. Robu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma

(2013) Lara Barazzuol et al.   Radiation Oncology

PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets

(2013) Girish M. Shah et al.   Frontiers in Oncology

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells

(2012) R. H. G. Wright et al.   GENES & DEVELOPMENT

Inheritance of Silent rDNA Chromatin Is Mediated by PARP1 via Noncoding RNA

(2012) Claudio Guetg et al.   MOLECULAR CELL

Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2

(2012) Claudia A. Doege et al.   NATURE

Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells

(2012) Somaira Nowsheen et al.   PLoS One

The Promise of Combining Inhibition of PI3K and PARP as Cancer Therapy

(2012) Farah L. Rehman et al.   Cancer Discovery

Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors

(2012) Janneke E. Jaspers et al.   Cancer Discovery

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

(2012) Ashish Juvekar et al.   Cancer Discovery

Dual Roles of PARP-1 Promote Cancer Growth and Progression

(2012) M. J. Schiewer et al.   Cancer Discovery

Regulation of chromatin structure by poly(ADP-ribosyl)ation

(2012) Sascha Beneke   Frontiers in Genetics

PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy

(2011) Pawel Domagala et al.   BREAST CANCER RESEARCH AND TREATMENT

Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer

(2011) J. Chad Brenner et al.   CANCER CELL

CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors

(2011) Victoria E. Anderson et al.   CANCER RESEARCH

Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition

(2011) Hidetaka Shibata et al.   CANCER SCIENCE

Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases

(2011) Jun-Xiang Zhang et al.   HEPATOLOGY

Poly (ADP-Ribose) Polymerase Inhibition Attenuates Atherosclerotic Plaque Development in ApoE-/- Mice with Hyperhomocysteinemia

(2011) Jiang-jiao Xie et al.   Journal of Atherosclerosis and Thrombosis

Poly(ADP-ribose) Polymerase 1 (PARP-1) Binds to 8-Oxoguanine-DNA Glycosylase (OGG1)

(2011) Nicole Noren Hooten et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft

(2011) J. M. Senra et al.   MOLECULAR CANCER THERAPEUTICS

SIRT6 Promotes DNA Repair Under Stress by Activating PARP1

(2011) Z. Mao et al.   SCIENCE

c-MYC Suppresses BIN1 to Release Poly(ADP-Ribose) Polymerase 1: A Mechanism by Which Cancer Cells Acquire Cisplatin Resistance

(2011) S. Pyndiah et al.   Science Signaling

Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics

(2010) Jin-xue He et al.   ACTA PHARMACOLOGICA SINICA

Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Effect of Chemotherapy in an Animal Model of Regional Therapy for the Treatment of Advanced Extremity Malignant Melanoma

(2010) Hiroaki Toshimitsu et al.   ANNALS OF SURGICAL ONCOLOGY

6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance

(2010) N. Issaeva et al.   CANCER RESEARCH

Poly(ADP-Ribose) Polymerase Inhibitor Induces Accelerated Senescence in Irradiated Breast Cancer Cells and Tumors

(2010) E. V. Efimova et al.   CANCER RESEARCH

How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation

(2010) Aswin Mangerich et al.   INTERNATIONAL JOURNAL OF CANCER

The Zn3 Domain of Human Poly(ADP-ribose) Polymerase-1 (PARP-1) Functions in Both DNA-dependent Poly(ADP-ribose) Synthesis Activity and Chromatin Compaction

(2010) Marie-France Langelier et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

(2010) Yvette Drew et al.   JNCI-Journal of the National Cancer Institute

PARP-1 Attenuates Smad-Mediated Transcription

(2010) Peter Lönn et al.   MOLECULAR CELL

The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets

(2010) Raga Krishnakumar et al.   MOLECULAR CELL

miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors

(2010) Patryk Moskwa et al.   MOLECULAR CELL

Chromatin regulation by Brg1 underlies heart muscle development and disease

(2010) Calvin T. Hang et al.   NATURE

PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy

(2010) E Salvati et al.   ONCOGENE

A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage

(2010) D. M. Chou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Poly(ADP-Ribose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology Targets

(2010) Anthony J. Chalmers et al.   SEMINARS IN RADIATION ONCOLOGY

Learning How to Read ADP-Ribosylation

(2009) Henning Kleine et al.   CELL

Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer

(2009) Qianben Wang et al.   CELL

Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?

(2009) M. Ali et al.   CLINICAL CANCER RESEARCH

In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016

(2009) A. L. Russo et al.   CLINICAL CANCER RESEARCH

ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors

(2009) J. P. Palma et al.   CLINICAL CANCER RESEARCH

The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer

(2009) Yvette Drew et al.   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications

(2009) Yvette Drew et al.   DRUG RESISTANCE UPDATES

Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors

(2009) Ana M. Mendes-Pereira et al.   EMBO Molecular Medicine

Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?

(2009) Gianluca Papeo et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Poly(ADP-ribose) Polymerase 1 Interacts with Nuclear Respiratory Factor 1 (NRF-1) and Plays a Role in NRF-1 Transcriptional Regulation

(2009) Mohammad B. Hossain et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PARP1 Poly(ADP-ribosyl)ates Sox2 to Control Sox2 Protein Levels andFGF4Expression during Embryonic Stem Cell Differentiation

(2009) Furong Gao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PolyADP-ribosylation is required for long-term memory formation in mammals

(2009) Shmuel Goldberg et al.   JOURNAL OF NEUROCHEMISTRY

Elevated Poly-(ADP-Ribose)-Polymerase Activity Sensitizes Retinoblastoma-Deficient Cells to DNA Damage-Induced Necrosis

(2009) H. Liu et al.   MOLECULAR CANCER RESEARCH

Epigenetic Silencing of the p16INK4a Tumor Suppressor Is Associated with Loss of CTCF Binding and a Chromatin Boundary

(2009) Michael Witcher et al.   MOLECULAR CELL

Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites

(2009) Matthias Altmeyer et al.   NUCLEIC ACIDS RESEARCH

Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer

(2009) N McCabe et al.   ONCOGENE

Parp1 Localizes within the Dnmt1 Promoter and Protects Its Unmethylated State by Its Enzymatic Activity

(2009) Michele Zampieri et al.   PLoS One

Activation of the abundant nuclear factor poly(ADP-ribose) polymerase-1 by Helicobacter pylori

(2009) C. W. Nossa et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler

(2009) A. J. Gottschalk et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Poly(ADP-ribose)-Dependent Regulation of DNA Repair by the Chromatin Remodeling Enzyme ALC1

(2009) D. Ahel et al.   SCIENCE

Domain C of Human Poly(ADP-ribose) Polymerase-1 Is Important for Enzyme Activity and Contains a Novel Zinc-Ribbon Motif†,‡

(2008) Zhihua Tao et al.   BIOCHEMISTRY

The role of DNA hypermethylation and demethylation in cancer and cancer therapy

(2008) Moshe Szyf   Current Oncology

Integrin-linked kinase regulates E-cadherin expression through PARP-1

(2008) Timothy R. McPhee et al.   DEVELOPMENTAL DYNAMICS

Development of PARP inhibitors in oncology

(2008) Jordi Rodon et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

CCCTC-binding Factor Activates PARP-1 Affecting DNA Methylation Machinery

(2008) Tiziana Guastafierro et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Poly(ADP-Ribose) Polymerase 1 Promotes Tumor Cell Survival by Coactivating Hypoxia-Inducible Factor-1-Dependent Gene Expression

(2008) M. Elser et al.   MOLECULAR CANCER RESEARCH

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reciprocal Binding of PARP-1 and Histone H1 at Promoters Specifies Transcriptional Outcomes

(2008) R. Krishnakumar et al.   SCIENCE

Toward specific functions of poly(ADP-ribose) polymerase-2

(2008) José Yélamos et al.   TRENDS IN MOLECULAR MEDICINE